Top Suppliers:I want be here
Related CAS#:
98326-33-1 1406-14-0
6138-79-0 127228-87-9
143851-98-3 929-73-7
65546-09-0 1135280-78-2
56-99-5 1406-02-6

98326-33-1

98326-33-1 structure
98326-33-1 structure
  • Name: Senazodan hydrochloride
  • Chemical Name: 6-[4-(4-Pyridinylamino)phenyl]-4,5-dihydro-3(2H)-pyridazinone hyd rochloride (1:1)
  • CAS Number: 98326-33-1
  • Molecular Formula: C15H15ClN4O
  • Molecular Weight: 302.75900
  • Catalog: Signaling Pathways Metabolic Enzyme/Protease Phosphodiesterase (PDE)
  • Create Date: 2016-06-16 10:42:09
  • Modify Date: 2024-01-12 12:19:54
  • Senazodan (MCI 154) (hydrochloride), as a Ca2+ sensitiser, shows inhibition effect on PDE III[1][2].
Name 6-[4-(4-Pyridinylamino)phenyl]-4,5-dihydro-3(2H)-pyridazinone hyd rochloride (1:1)
Description Senazodan (MCI 154) (hydrochloride), as a Ca2+ sensitiser, shows inhibition effect on PDE III[1][2].
Related Catalog
Target

PDE III[1]

In Vitro Senazodan (hydrochloride) seems to affect directly the actin-myosin crossbridge kinetics, and increases myosin ATPase activity[1]. Senazodan (hydrochloride) produces a concentration-dependent increase in tension development. Senazodan (hydrochloride) enhances Ca2+ binding to myofilaments and to purified cardiac troponin C. Senazodan (hydrochloride) also enhances contractility in guinea-pig papillary muscles by inhibiting PDE III[2].Senazodan (0.1 nM~0.1 mM) (hydrochloride) shows that the contractile response of superior mesenteric arterie (SMA) to norepinephrine (NE) after hemorrhagic shock is significantly decreased as compared with the normal control group. Senazodan (0.01 mM) (hydrochloride) pretreatment prevents the effects of Ang II, and the concentration-response curve of Ca2+ is shifted to the right as compared with Ang II-alone group[3].
In Vivo Senazodan (0.1~2.0 mg/kg; left femoral vein catheterization infusion) (hydrochloride) decreases the pressor effect of norepinephrine (NE)[3]. Senazodan (0.1 mg/kg; i.v.) (hydrochloride) makes LVSP, IP, MC, and Lo all increased significantly, while heart rate is not obviously changed and left ventricular end-diastolic pressure (LVEDP) is reduced remarkably[4]. Animal Model: Wistar rats (200~250 g)[3] Dosage: 0.1~2.0 mg/kg Administration: Left femoral vein catheterization infusion Result: Decreased the pressor effect of norepinephrine (NE). Animal Model: Rabbits[4] Dosage: 0.1 mg/kg Administration: I.v. Result: LVSP, IP, MC, and Lo all were increased significantly while heart rate was not obviously changed and left ventricular end-diastolic pressure (LVEDP) was reduced remarkably.
References

[1]. Lehtonen LA, et al. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43(3):187-203.

[2]. Erhardt L. An emerging role for calcium sensitisation in the treatment of heart failure. Expert Opin Investig Drugs. 2005 Jun;14(6):659-70.

[3]. Yang G, et al. Effects of MCI-154 on vascular reactivity and its mechanisms after hemorrhagic shock in rats. J Cardiovasc Pharmacol. 2006;47(6):751-757.

[4]. Ming MJ, et al. Effects of MCI-154, a calcium sensitizer, on cardiac dysfunction in endotoxic shock in rabbits. Shock. 2000;13(6):459-463.
Boiling Point 492.4ºC at 760 mmHg
Molecular Formula C15H15ClN4O
Molecular Weight 302.75900
Flash Point 251.6ºC
Exact Mass 302.09300
PSA 73.10000
LogP 2.37470

Chemsrc provides CAS#:98326-33-1 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 98326-33-1 | Chemsrc address: https://m.chemsrc.com/en/baike/458170.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved